Local control for intermediate-risk rhabdomyosarcoma: Results from D9803 according to histology, group, site, and size: A report from the children's oncology group

Suzanne L. Wolden, Elizabeth R. Lyden, Carola A. Arndt, Douglas S. Hawkins, James R. Anderson, David A. Rodeberg, Carol D Morris, Sarah S. Donaldson

Research output: Contribution to journalArticle

Abstract

Purpose To determine local control according to clinical variables for patients with intermediate-risk rhabdomyosarcoma (RMS) treated on Children's Oncology Group protocol D9803. Patients and Methods Of 702 patients enrolled, we analyzed 423 patients with central pathology-confirmed group III embryonal (n=280) or alveolar (group III, n=102; group I-II, n=41) RMS. Median age was 5 years. Patients received 42 weeks of VAC (vincristine, dactinomycin, cyclophosphamide) or VAC alternating with VTC (T = topotecan). Local therapy with 50.4 Gy radiation therapy with or without delayed primary excision began at week 12 for group III patients. Patients with group I/II alveolar RMS received 36-41.4 Gy. Local failure (LF) was defined as local progression as a first event with or without concurrent regional or distant failure. Results At a median follow-up of 6.6 years, patients with clinical group I/II alveolar RMS had a 5-year event-free survival rate of 69% and LF of 10%. Among patients with group III RMS, 5-year event-free survival and LF rates were 70% and 19%, respectively. Local failure rates did not differ by histology, nodal status, or primary site, though there was a trend for increased LF for retroperitoneal (RP) tumors (P=.12). Tumors ≥5 cm were more likely to fail locally than tumors

Original languageEnglish (US)
Pages (from-to)1071-1076
Number of pages6
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume93
Issue number5
DOIs
StatePublished - Dec 1 2015

Fingerprint

histology
Rhabdomyosarcoma
Histology
Alveolar Rhabdomyosarcoma
tumors
Dactinomycin
Vincristine
Cyclophosphamide
Disease-Free Survival
Topotecan
Radiation Dosage
Neoplasms
pathology
progressions
radiation therapy
therapy
Radiotherapy
Survival Rate
Pathology
trends

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Local control for intermediate-risk rhabdomyosarcoma : Results from D9803 according to histology, group, site, and size: A report from the children's oncology group. / Wolden, Suzanne L.; Lyden, Elizabeth R.; Arndt, Carola A.; Hawkins, Douglas S.; Anderson, James R.; Rodeberg, David A.; Morris, Carol D; Donaldson, Sarah S.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 93, No. 5, 01.12.2015, p. 1071-1076.

Research output: Contribution to journalArticle

Wolden, Suzanne L. ; Lyden, Elizabeth R. ; Arndt, Carola A. ; Hawkins, Douglas S. ; Anderson, James R. ; Rodeberg, David A. ; Morris, Carol D ; Donaldson, Sarah S. / Local control for intermediate-risk rhabdomyosarcoma : Results from D9803 according to histology, group, site, and size: A report from the children's oncology group. In: International Journal of Radiation Oncology, Biology, Physics. 2015 ; Vol. 93, No. 5. pp. 1071-1076.
@article{53e585a80e9b4d5d8b448412580e6ef6,
title = "Local control for intermediate-risk rhabdomyosarcoma: Results from D9803 according to histology, group, site, and size: A report from the children's oncology group",
abstract = "Purpose To determine local control according to clinical variables for patients with intermediate-risk rhabdomyosarcoma (RMS) treated on Children's Oncology Group protocol D9803. Patients and Methods Of 702 patients enrolled, we analyzed 423 patients with central pathology-confirmed group III embryonal (n=280) or alveolar (group III, n=102; group I-II, n=41) RMS. Median age was 5 years. Patients received 42 weeks of VAC (vincristine, dactinomycin, cyclophosphamide) or VAC alternating with VTC (T = topotecan). Local therapy with 50.4 Gy radiation therapy with or without delayed primary excision began at week 12 for group III patients. Patients with group I/II alveolar RMS received 36-41.4 Gy. Local failure (LF) was defined as local progression as a first event with or without concurrent regional or distant failure. Results At a median follow-up of 6.6 years, patients with clinical group I/II alveolar RMS had a 5-year event-free survival rate of 69{\%} and LF of 10{\%}. Among patients with group III RMS, 5-year event-free survival and LF rates were 70{\%} and 19{\%}, respectively. Local failure rates did not differ by histology, nodal status, or primary site, though there was a trend for increased LF for retroperitoneal (RP) tumors (P=.12). Tumors ≥5 cm were more likely to fail locally than tumors",
author = "Wolden, {Suzanne L.} and Lyden, {Elizabeth R.} and Arndt, {Carola A.} and Hawkins, {Douglas S.} and Anderson, {James R.} and Rodeberg, {David A.} and Morris, {Carol D} and Donaldson, {Sarah S.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.ijrobp.2015.08.040",
language = "English (US)",
volume = "93",
pages = "1071--1076",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Local control for intermediate-risk rhabdomyosarcoma

T2 - Results from D9803 according to histology, group, site, and size: A report from the children's oncology group

AU - Wolden, Suzanne L.

AU - Lyden, Elizabeth R.

AU - Arndt, Carola A.

AU - Hawkins, Douglas S.

AU - Anderson, James R.

AU - Rodeberg, David A.

AU - Morris, Carol D

AU - Donaldson, Sarah S.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Purpose To determine local control according to clinical variables for patients with intermediate-risk rhabdomyosarcoma (RMS) treated on Children's Oncology Group protocol D9803. Patients and Methods Of 702 patients enrolled, we analyzed 423 patients with central pathology-confirmed group III embryonal (n=280) or alveolar (group III, n=102; group I-II, n=41) RMS. Median age was 5 years. Patients received 42 weeks of VAC (vincristine, dactinomycin, cyclophosphamide) or VAC alternating with VTC (T = topotecan). Local therapy with 50.4 Gy radiation therapy with or without delayed primary excision began at week 12 for group III patients. Patients with group I/II alveolar RMS received 36-41.4 Gy. Local failure (LF) was defined as local progression as a first event with or without concurrent regional or distant failure. Results At a median follow-up of 6.6 years, patients with clinical group I/II alveolar RMS had a 5-year event-free survival rate of 69% and LF of 10%. Among patients with group III RMS, 5-year event-free survival and LF rates were 70% and 19%, respectively. Local failure rates did not differ by histology, nodal status, or primary site, though there was a trend for increased LF for retroperitoneal (RP) tumors (P=.12). Tumors ≥5 cm were more likely to fail locally than tumors

AB - Purpose To determine local control according to clinical variables for patients with intermediate-risk rhabdomyosarcoma (RMS) treated on Children's Oncology Group protocol D9803. Patients and Methods Of 702 patients enrolled, we analyzed 423 patients with central pathology-confirmed group III embryonal (n=280) or alveolar (group III, n=102; group I-II, n=41) RMS. Median age was 5 years. Patients received 42 weeks of VAC (vincristine, dactinomycin, cyclophosphamide) or VAC alternating with VTC (T = topotecan). Local therapy with 50.4 Gy radiation therapy with or without delayed primary excision began at week 12 for group III patients. Patients with group I/II alveolar RMS received 36-41.4 Gy. Local failure (LF) was defined as local progression as a first event with or without concurrent regional or distant failure. Results At a median follow-up of 6.6 years, patients with clinical group I/II alveolar RMS had a 5-year event-free survival rate of 69% and LF of 10%. Among patients with group III RMS, 5-year event-free survival and LF rates were 70% and 19%, respectively. Local failure rates did not differ by histology, nodal status, or primary site, though there was a trend for increased LF for retroperitoneal (RP) tumors (P=.12). Tumors ≥5 cm were more likely to fail locally than tumors

UR - http://www.scopus.com/inward/record.url?scp=84946782212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946782212&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2015.08.040

DO - 10.1016/j.ijrobp.2015.08.040

M3 - Article

C2 - 26581144

AN - SCOPUS:84946782212

VL - 93

SP - 1071

EP - 1076

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -